Press-release for stocks for arcutis biotherapeutics, inc.

Prices are updated after-hours

Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff
Published: 2021-02-18 (Crawled : 14:03) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M

| -71.18% | O: -1.46% H: 5.36% C: 1.3%

| -71.21% | O: 1.43% H: 0.82% C: -5.31%
offering

Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis
Published: 2021-01-20 (Crawled : 14:03) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M

| -64.83% | O: 0.77% H: 1.28% C: -2.52%
dermatitis phase 3 treatment

Matthew Moore Joins Arcutis as Chief Business Officer
Published: 2021-01-11 (Crawled : 14:03) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M

| -64.13% | O: -1.95% H: 3.19% C: 0.65%

| -61.76% | O: 0.98% H: 5.85% C: 5.7%
drug

67%

33%

AGBA | News | $1.26 215.0% 68.25% 130M

EGOX | $0.0515 43.06% 30.1% 330M

OLB 4 | $0.33 -14.95% 25.53% 840K

NVFY | $2.77 31.28% 23.83% 33M

ZCMD | $1.87 28.97% 22.46% 31M

RCON | $0.1112 13.01% 21.28% 1.7M

INSG | $3.03 25.21% 20.13% 330K

GCTK | $0.8191 22.25% 18.2% 190K

WLGS | $0.59 18.0% 17.9% 2.3M

ASNS | $0.828 21.75% 17.86% 18K

Save your searches and get alerts when important news are released.